Prednisone vs. MTX: a draw after 24 weeks

Pulmonary sarcoidosis remains a persistent clinical challenge in respiratory medicine. Although glucocorticoids have long been the mainstay of first-line therapy, their side effects often complicate long-term treatment. In recent years, methotrexate has been considered a viable second-line option, but to date no reliable direct comparison with first-line corticosteroids has been performed.